Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes

Patent metadata

Field	Value
Publication number	US-11110111-B2
Application number	US-201916583852-A
Country	US
Kind code	B2
Filing date	Sep 26, 2019
Priority date	Jun 17, 2015
Publication date	Sep 7, 2021
Grant date	Sep 7, 2021

Abstract

The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.

First claim

The invention claimed is:

1. A method of treating mitochondrial DNA depletion syndrome in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one deoxynucleoside, wherein the mitochondrial DNA depletion syndrome is characterized by at least one mutation in a gene chosen from the group consisting of: DGUOK; TYMP; and RRM2B, and the therapeutically effective amount is between about 100 mg/kg/day and about 1000 mg/kg/day.

2. The method of claim 1 , wherein the composition comprises two or more deoxynucleosides.

3. The method of claim 1 , wherein the deoxynucleoside is chosen from the group consisting of deoxycytidine (dC), deoxythymidine (dT), deoxyadenosine (dA), deoxyguanosine (dG), and mixtures thereof.

4. A method of treating mitochondrial DNA depletion syndrome in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one deoxynucleoside, wherein the mitochondrial DNA depletion syndrome is characterized by at least one mutation in a gene chosen from the group consisting of: DGUOK; TYMP; and RRM2B, and the therapeutically effective amount is between about 200 mg/kg/day and about 800 mg/kg/day.

5. A method of treating mitochondrial DNA depletion syndrome in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one deoxynucleoside, wherein the mitochondrial DNA depletion syndrome is characterized by at least one mutation in a gene chosen from the group consisting of: DGUOK; TYMP; and RRM2B, and, the therapeutically effective amount is between about 250 mg/kg/day and about 400 mg/kg/day.

6. The method of claim 1 , wherein the composition comprises more than one deoxynucleoside and the therapeutically effective amount is between about 100 mg/kg/day and about 1000 mg/kg/day of each deoxynucleoside in the composition.

7. The method of claim 1 , wherein the composition comprises more than one deoxynucleoside and the therapeutically effective amount is between about 100 mg/kg/day and about 1000 mg/kg/day of the total deoxynucleoside in the composition.

8. The method of claim 1 , wherein the composition is administered once daily, twice daily, three times daily, four times daily, five times daily or six times daily.

9. The method of claim 1 , wherein the composition is administered orally, intrathecally, enterally, or intravenously.

10. The method of claim 9 , wherein the composition is administered orally and comprises one or more deoxynucleosides mixed with cow's milk, human breast milk, infant formula or water.

11. The method of claim 1 , further comprising administering to the subject an additional agent chosen from the group consisting of an inhibitor of thymidine phosphorylase and an inhibitor of cytidine deaminase.

12. The method of claim 1 , wherein the therapeutically effective amount of the composition administered to the subject is increased over time.

13. The method of claim 12 , wherein a first therapeutically effective amount of the composition administered to the subject is about 100 mg/kg/day of composition, and wherein the therapeutically effective amount of the composition is increased over time to 200 mg/kg/day, to 400 mg/kg/day, to 800 mg/kg/day, up to 1000 mg/kg/day.

14. The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable carrier.

15. The method of claim 1 , further comprising monitoring the subject for an adverse effect after the administration of the composition, wherein if an adverse effect is observed, the therapeutically effective amount of the composition is decreased.

16. The method of claim 15 , further comprising monitoring the subject for the observed adverse effect after the therapeutically effective amount of the composition is decreased, wherein if the adverse effect is no longer observed, the therapeutically effective amount of the composition is increased.

Assignees

• Univ Columbia

Inventors

• Hirano Michio
• Garone Caterina
• Marti Ramon

Classifications

• A61K31/7068 Primary

  having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61K31/7072 Primary

  having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title